| |
| |
|
| Insider
Information: |
Fuchs Henry J |
| Relationship: |
|
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
222,228 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$18,063,061 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
222,228 |
|
|
| Total
Value |
$18,063,061 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Onyx Pharmaceuticals Inc |
ONXX |
EVP & Chief Medical Of... |
2008-11-18 |
14,891 |
2006-05-15 |
0 |
Premium* |
|
|
Ardea Biosciences Inc |
RDEA |
Director |
2012-06-19 |
0 |
2007-12-05 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
President, Worldwide R&D |
2024-03-15 |
196,872 |
2009-03-02 |
0 |
Premium* |
|
|
Genomic Health Inc |
GHDX |
Director |
2019-11-08 |
0 |
2014-04-01 |
0 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
|
2023-01-20 |
10,465 |
2020-01-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
294 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 10 of 12
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2014-01-02 |
4 |
AS |
$68.97 |
$63,172 |
D/D |
(916) |
42,350 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2013-09-05 |
4 |
AS |
$70.00 |
$700,000 |
D/D |
(10,000) |
43,266 |
0 |
- |
|
| GHDX |
Genomic Health Inc |
Director |
– • – |
2018-10-01 |
4 |
A |
$70.18 |
$9,966 |
D/D |
142 |
6,177 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2017-04-28 |
4 |
A |
$70.30 |
$21,232 |
D/D |
302 |
140,494 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2020-03-20 |
4 |
D |
$73.05 |
$426,320 |
D/D |
(5,836) |
139,869 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2021-03-16 |
4 |
D |
$77.21 |
$174,417 |
D/D |
(2,259) |
108,596 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2022-03-15 |
4 |
D |
$78.27 |
$947,145 |
D/D |
(12,101) |
146,012 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2021-03-15 |
4 |
D |
$78.39 |
$584,789 |
D/D |
(7,460) |
110,855 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2021-03-22 |
4 |
D |
$78.52 |
$192,688 |
D/D |
(2,454) |
106,142 |
0 |
- |
|
| GHDX |
Genomic Health Inc |
Director |
– • – |
2019-02-25 |
4 |
S |
$78.88 |
$278,226 |
D/D |
(3,521) |
6,332 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2018-03-02 |
4 |
D |
$79.86 |
$205,719 |
D/D |
(2,576) |
151,309 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2018-04-02 |
4 |
AS |
$80.12 |
$801,200 |
D/D |
(10,000) |
156,676 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2013-09-19 |
4 |
AS |
$80.19 |
$801,900 |
D/D |
(10,000) |
43,266 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2022-03-16 |
4 |
D |
$80.72 |
$182,346 |
D/D |
(2,259) |
143,753 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2016-05-06 |
4 |
D |
$80.80 |
$252,985 |
D/D |
(3,131) |
117,950 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2018-03-22 |
4 |
D |
$81.36 |
$472,864 |
D/D |
(5,812) |
156,676 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2018-03-22 |
4/A |
D |
$81.36 |
$474,736 |
D/D |
(5,835) |
156,653 |
0 |
- |
|
| GHDX |
Genomic Health Inc |
Director |
– • – |
2019-02-22 |
4 |
S |
$81.70 |
$2,168,403 |
D/D |
(26,479) |
6,332 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2016-02-29 |
4 |
D |
$81.87 |
$4,622,708 |
D/D |
(56,464) |
103,919 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2016-05-13 |
4 |
D |
$82.71 |
$168,398 |
D/D |
(2,036) |
115,914 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2018-03-15 |
4 |
D |
$83.57 |
$406,234 |
D/D |
(4,861) |
146,448 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2024-03-15 |
4 |
D |
$83.87 |
$2,808,387 |
D/D |
(33,485) |
196,872 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2020-03-13 |
4 |
D |
$84.50 |
$886,912 |
D/D |
(10,496) |
127,485 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2024-03-05 |
4 |
S |
$85.18 |
$3,010,396 |
D/D |
(35,341) |
212,117 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2014-11-10 |
4 |
S |
$86.55 |
$1,730,982 |
D/D |
(20,000) |
76,550 |
0 |
- |
|
294 Records found
|
|
Page 10 of 12 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
